Potential therapies that reduce the presence of HLA-G in tumors or suppress its transcription prove to enhance the efficacy of NK cells in lysing tumor cells, especially in patients with CLL. This evidence concerns the gene HLA-G and B-cell chronic lymphocytic leukemia.